
    
      1. To determine the safety and toxicity of intravenous docetaxel, administered on a weekly
           schedule (3 weeks out of 4), in combination with oral lonafarnib, administered on a
           daily schedule, in patients with locally advanced and metastatic solid tumor
           malignancies which are refractory to the standard of care.

        2. To determine the pharmacokinetic interaction between docetaxel and lonafarnib.

        3. To determine the molecular interaction in peripheral blood mononuclear cells between
           docetaxel and lonafarnib
    
  